

VOLUME 2, SUBJECT INDEX

- Adapter tags, 21–27
- AIDS virus, murine, PCR detection, 272–274
- Allele frequencies, rapid determination of at loci exhibiting length polymorphism, 313–317
- Allele-specific PCR. *See also* Mismatch amplification mutation assay
- Amplicons, methods for detection, 1–9
- Amplification, DNA
- effect of RNA concentration on cDNA synthesis for, 86–88
 - from formalin-fixed tissue biopsy, 175–176
 - linear range of, 1–9
 - whole cDNA populations, strategies for, 185–190
- Amplimers
- partial sulfurization of and inhibition of degradation by Vent and *Taq* polymerases, 131–136
 - with 3'-terminal phosphothioate linkages, retard degradation and diminish mispriming, 131–136
- Anchored PCR, use of for amplification and cloning of sugarcane sucrose synthases, 70–75
- Apolipoprotein E genotyping, rapid semiautomated method for, 348–350
- Artifacts, and DNA amplification from formalin-fixed tissue biopsy, 175–176
- Astrocyte mRNAs, quantitation with method for rapid generation of deletion constructs, 66–69
- Asymmetric PCR, construction of subtracted cDNA library with, 204–209
- Automation
- for apolipoprotein E genotyping, 348–350
 - detection of *Chlamydia trachomatis*, 167–171
 - diagnosis of β -thalassemia, 163–166
 - facilitation with PCR buffer optimization, 234–240
- Autopsied tissue, PCR-based genetic analysis of DNA from, 354–355
- Bacteriophage plaques, PCR characterization, 93–95
- Beta-thalassemia, detection of common mutations of using MARMS, 163–166
- Blood
- dried, method of extracting DNA from, 177–179
 - Guthrie spots, direct PCR of for cystic fibrosis genotyping, 154–156
 - improved sample processing of for PCR, 149–153
- BLV. *See* Bovine leukemia virus
- Booster PCR, increased specificity for SSCP with, 45–50
- Bovine leukemia virus proviral DNA, detection in individual cells, 333–340
- Bubble tags, 21–27
- Buffer, optimization of to facilitate PCR automation, 234–240
- c-Ha-ras, measurement of mutation using MAMA, 14–20
- Capillary PCR, sample preparation for, 261–262
- 6-Carboxy 4',5'-dichloro-2',7'-dimethoxy fluorescein, synthesis, labeling, purification, and quantification of oligonucleotides labeled with, 223–227
- cDNA
- subtracted library, construction with asymmetric PCR, 204–209
 - synthesis, for DNA amplification, effect of RNA concentration on, 86–88
 - whole sequences, amplification of with rPCR, 185–190
 - large, cloning of with anchored PCR, 70–75
- CF. *See* Cystic fibrosis
- Chelex 100, use of to reverse inhibitory effect of heparin on PCR, 356–358
- Chemiluminescence
- for detection of amplicons, 1–9
 - detection of DNA, and PCR, 228–233
- Chlamydia trachomatis*, immunogenetic recovery of from urine and colorimetric DNA detection, 167–171
- Chromatin, analysis of structure of by ligation-mediated PCR, 107–111
- Cloning
- of unknown sequence with dU-containing linkers, 328–332
 - PCR fragments, improved method for using tailing procedure and overhangs, 81–82
- Cohesive ends, UDG-mediated, 328–332
- Colinear genes, selective detection of, 258–260
- Colorimetric DNA detection, *Chlamydia trachomatis* after immunomagnetic recovery from urine, 167–171
- Competitive PCR analysis, rapid method for synthesis of DNA fragments, 66–69
- Conservation, evolutionary, PCR demonstration of for SRY-box motif, 218–222
- Control templates, 91–92
- Corynebacteria diphtheriae*, PCR assay, 91–92
- Cystic fibrosis
- detection of delta F508 mutation with allele-specific PCR primers and time-resolved fluorometry, 157–162
 - genotyping by direct PCR of Guthrie blood spots, 154–156
- Degenerate primers, use of with *Pfu* DNA polymerase for PCR, 346–347
- Degradation, by Vent polymerase, is retarded by amplimers with 3'-terminal phosphothioate linkages, 131–136
- Deletion artifacts, of tandem repeats during PCR, effect of primer selection on, 263–265
- Deletion constructs, method for generating for competitive PCR assays, 66–69
- Denaturing gradient gel electrophoresis with automated sequencing, rapid characterization of HIV-1 sequence diversity with, 293–300
- detection limits of and detection of trace components in DNA templates, 112–116
 - and determination of Vent DNA polymerase fidelity, 288–292
 - method for attachment of universal 50-bp GC-clamp to PCR fragments for, 83–85
- Deoxyinosine, PCR with degenerate primers containing, fails with *Pfu* DNA polymerase, 346–347
- DGGE. *See* Denaturing gradient gel electrophoresis
- DIANA. *See* Immunomagnetic separation
- Dimethyl sulfoxide, optimum concentration of in PCR influenced by sequence within primer, 89–90
- Dimethylsulfate, genomic footprinting with, 107–111
- DMS. *See* Dimethylsulfate
- DMSO. *See* Dimethyl sulfoxide
- DN-PCR. *See* Double-nested PCR
- DNA
- BLV proviral, detection in individual cells, 333–340
 - deletion constructs, rapid synthesis of for mRNA quantitation, 66–69
 - flanking, amplification of up to 4.4 kb of, 197–203
 - large, ligation-mediated PCR of restriction fragments from, 21–27
 - megabase, amplification with rPCR, 185–190

- method for extraction from Guthrie cards, 177–179
- methylation patterns, LMPCR analysis, 107–111
- PCR-amplified, variables for enhancing in situ hybridization detection of, 305–312
- profiling, automated, by fluorescent labeling of PCR products, 34–40
- quantitative analysis, PCR standards for, 1–9
- sequence element, saturation mutagenesis with Mod-PCR 210–217
- templates, PCR detection of trace components, 112–116
- DNA-binding protein, single-stranded, use of in direct PCR sequencing of murine Ig gene, 99–101
- DNA polymerase
- Pfu*, use of degenerate primers with for PCR, 346–347
 - thermophilic, properties of, 275–287
 - Vent, mutations induced by during DNA amplification, 288–292
- DNA polymerase I, *Thermus aquaticus*, expression, purification, and enzymatic characterization, 275–287
- DNase I, genomic footprinting with, 107–111
- Double-nested PCR, compared with heminested PCR, 241–249
- dU excision, by UDG to create cohesive ends on PCR fragments, 328–332
- Endonuclease digestion mapping, partial, PCR for, 228–233
- F-SSCP. *See* Fluorescence single-strand conformation polymorphism
- Failure, method for detecting in PCR, 91–92
- False-negative reactions, method for detecting, 91–92
- Fam-Oliglow labeling method, effect in F-SCCP, 10–13
- Ficoll-Hypaque, versus Roche Specimen Washing Solution for PBL separation, 149–153
- Fidelity, Vent DNA polymerase, 288–292
- Fixation time, effect on in situ hybridization detection of PCR-amplified DNA, 305–312
- Fixatives, effect on in situ hybridization detection of PCR-amplified DNA, 305–312
- FluorePrime labeling method, effect in F-SCCP, 10–13
- Fluorescence single-strand conformation polymorphism analysis, 10–13
- for detection of multiple point mutations, 323–326
- Fluorescent dye, synthesis and characterization of oligonucleotides labeled with, 223–227
- Fluorescent labeling, PCR products, automated DNA profiling with, 34–40
- Fluorometry, time-resolved, use of with allele-specific PCR primers to detect delta F508 cystic fibrosis mutation, 157–162
- Footprinting, genomic
- with DMS, 107–111
 - with DNase I, 107–111
 - in vivo, with UV light, 107–111
- Formalin-fixed tissue biopsy, reliable typing of DNA amplified from, 175–176
- gag* target DNA, HIV, detection with closed reaction tube nested PCR method, 60–65
- GC-clamp, universal 50-bp, attachment to PCR fragments, use in mutation analysis by DGGE, 83–85
- Gene synthesis, method using overlap extension technique, 266–271
- Genomic mapping, and long-distance PCR, 51–59
- Genomic walking, 2- to 4-kb steps, with panhandle PCR, 197–203
- Genotyping, apolipoprotein E, rapid semiautomated method for, 348–350
- Guthrie blood spots, direct PCR of for cystic fibrosis genotyping, 154–156
- Guthrie cards, method for extraction of DNA from, 177–179
- HCV. *See* Hepatitis C virus
- Heminested PCR
- compared with double-nested PCR, 241–249
 - detection of HCV in plasma with, 241–249
- Heparin, inhibitory effect on PCR, method for reversing in HLA class II typing, 356–358
- Hepatitis B virus, PCR analysis, 191–196
- Hepatitis C virus, detection in plasma with heminested PCR, 241–249
- Heteroduplex DNA, double-stranded, detection of p53 mutations in human tumors as, 96–98
- Heteroduplex formation, modeling of during PCR from mixtures of DNA templates, 112–116
- HLA class II typing, method for reversing inhibitory effect of heparin on PCR for, 356–358
- HN-PCR. *See* Heminested PCR
- Hot start method
- effect on in situ hybridization detection of PCR-amplified DNA, 305–312
 - as factor in quantitation, 1–9
- Human immunodeficiency virus type 1 *gag* target DNA, detection with closed reaction tube nested DNA method, 60–65
- PCR analysis, 191–196
- rapid characterization of sequence diversity with DGGE and automated sequencing, 293–300
- use of quantitative PCR to monitor DNA in blood, 1–9
- Hybrid-selection, use of to increase PCR specificity, 41–44
- Immunoglobulin genes, murine, direct PCR sequencing using *E. coli* single-stranded DNA protein, 99–101
- Immunomagnetic separation, *Chlamydia trachomatis*, 167–171
- IMS. *See* Immunomagnetic separation
- In situ hybridization, variable for enhancing detection of PCR-amplified DNA, 305–312
- In situ PCR, 305–312
- reverse transcriptase, RNA targets, 117–123
- Invisible mending, method to abolish mimicked restriction site, 328–332
- JOE. *See* 6-Carboxy 4',5'-dichloro-2',7'-dimethoxy fluorescein
- Large cDNAs, cloning of with anchored PCR, 70–75
- Length polymorphism, rapid determination of allele frequencies at loci with, 313–317
- Ligation-mediated PCR
- analysis of chromatin structure, 107–111
 - restriction fragments from large DNA molecules, 21–27
- LMPCR. *See* Ligation-mediated PCR
- LOH. *See* Loss of heterozygosity
- Long-distance PCR, optimization with transposon-based model system, 51–59
- Loss of heterozygosity, PCR analysis of, 354–355
- MAIDS virus, PCR detection, 272–274
- MAMA. *See* Mismatch amplification mutation assay

- MARMS. *See* Multiple amplification refractory mutation system
- Measles virus, reverse transcriptase in situ PCR detection in HeLa and Dami cells, 117–123
- Methylation patterns, DNA, LMPCR analysis, 107–111
- Mismatch amplification mutation assay, 14–20
- Mispriming, by *Taq* polymerase, reduced by amplimers with 3'-terminal phosphothioate linkages, 131–136
- Mod-PCR, generation of random base substitution mutations in DNA sequence element, 210–217
- Multiple amplification refractory mutation system, detection of common β -thalassemia mutations with, 163–166
- Mutagenesis PCR
 avoiding in unwanted mutations in, 253–257
 randomization of genes by, 28–33
 saturation, with Mod-PCR, 210–217
 site-directed, PCR and UDG method for, 124–130
- Mutagenic oligonucleotide-directed PCR, generation of random base substitution mutations in DNA sequence element, 210–217
- Mutations
 detection with F-SSCP, 10–13
 measurement of in c-Ha-ras using MAMA, 14–20
 misincorporation, unwanted mutations occurring during PCR, 253–257
 random, generation of in DNA sequence element with Mod-PCR, 210–217
 random point, PCR-derived library of in V3 region of SIV, 301–304
 Taq polymerase terminal transferase-like activity-generated, 253–257
 unwanted, avoiding in PCR mutagenesis, 253–257
- Nested PCR, method with closed reaction tubes, 60–65
- Nucleic acids, quantitation with PCR, 1–9
- Nucleotide repeat polymorphic sequences, PCR analysis of in autopsied tissue, 354–355
- Oligonucleotides, 5'-fluorescent-dye-labeled, synthesis and characterization, 223–227
- Optimization, amplification step, as factor in quantitation, 1–9
- Overhangs, and tailing procedure, improved method for cloning PCR fragments, 81–82
- Overlap extension technique, method of total gene synthesis using, 266–271
- ³²P-labeled nucleotides, for detection of amplicons, 1–9, 261–262
- p53 gene
 detection of loss of heterozygosities of in tumor tissues with F-SSCP, 10–13
 detection of mutations in tumors as single-stranded conformation polymorphs and double-stranded heteroduplex DNA, 96–98
- p53 genomic DNA, two-stage PCR of exons 5–9, 250–252
- p53 sequence, use of booster PCR to improve specificity and yield for SSCP, 45–50
- Panhandle PCR, genomic walking with, 197–203
- Paraffin wax, use of as vapor barrier in PCR, 180–181
- PBL. *See* Peripheral blood lymphocytes PCR
 allele-specific. *See also* Mismatch amplification mutation assay
 allele-specific primers, use of with time-resolved fluorometry to detect delta F508 cystic fibrosis mutation, 157–162
 amplification of mixed allelic templates in direct proportion to stoichiometric fraction of each, 112–116
 analysis of DNA from Guthrie cards, 177–179
 anchored, use for amplification and cloning of sugarcane sucrose synthase cDNA, 70–75
 asymmetric, construction of subtracted cDNA library with, 204–209
 capillary, sample preparation for, 261–262
 characterization of bacteriophage plaques, 93–95
 colorimetric assay, combined with immunomagnetic recovery of *Chlamydia trachomatis* from urine, 167–171
 competitive, 191–196
 demonstration of evolutionary conservation of SRY-box motif, 218–222
 detection of MAIDS virus, 272–274
 direct, of Guthrie blood spots for cystic fibrosis genotyping, 154–156
 effect of primer selection on artifactual deletion of tandem repeat during, 263–265
 heminested, detection of HCV in plasma with, 241–249
 hybrid-selected, 41–44
 improved blood sample processing for, 149–153
 in situ, 305–312
 ligation-mediated
 analysis of chromatin structure, 107–111
 of restriction fragments from large DNA molecules, 21–27
 long-distance, optimization with transposon-based model system, 51–59
 method for detecting failure, 91–92
 and modified reverse transcription, for selective detection of colinear genes, 258–260
 multiplex, use of to detect common mutations of β -thalassemia, 163–166
 mutagenic oligonucleotide-directed, generation of random base substitution mutations in DNA sequence element, 210–217
 nested, method with closed reaction tubes, 60–65
 panhandle, genomic walking with, 197–203
 for partial endonuclease digestion mapping, 228–233
 quantitation of endomycorrhizal fungi colonizing roots by, 76–80
 quantitative
 strategies for, 191–196
 versus semi-quantitative, 1–9
 in virology, 191–196
 RACE, lock-docking oligo(dT) primer for 5' and 3', 144–148
 random, amplification of whole cDNA sequences with, 185–190
 restriction-site, for unknown sequence retrieval, 318–322
 reverse transcriptase
 competitive, 191–196
 in situ, RNA targets, 117–123
 quantitative, in virology, 191–196
 rapid, analysis of rare gene transcripts quantitatively with, 137–143
 reverse transcription, use of stock solutions to simplify mRNA quantitation, 351–353
 sequence-independent, 185–190
 small-volume, sample preparation for, 261–262

- specificity increased
 with booster PCR for SSCP, 45–50
 by use of hybrid-selected template, 41–44
 total gene synthesis method using overlap extension technique, 266–271
 transposon-based, and long-distance PCR, 51–59
 two-stage, of p53 genomic DNA exons 5–9, 250–252
 and UDG, method for site-directed mutagenesis, 124–130
 understanding assay limits, 1–9
 use of paraffin wax as vapor barrier, 180–181
 using DNA generated by to generate truncated proteins, 172–174
- PCR-amplified DNA, variables for enhancing in situ hybridization detection of, 305–312
- PCR fragments
 and attachment of universal 50-bp GC-clamp, use in mutation analysis by DGGE, 83–85
 cloning, improved method for using tailing procedure and overhangs, 81–82
- PCR mutagenesis
 avoiding unwanted mutations, 253–257
 randomization of genes by, 28–33
- PCR products
 automated DNA profiling of by fluorescent labeling, 34–40
 Ig gene, direct sequencing of by inclusion of *E. coli* ssDNA binding protein, 99–101
- PCR-single-strand conformation polymorphism. *See also* Fluorescence single-strand conformation analysis
- Peripheral blood lymphocytes, separation and extraction method for amplification with *Taq* polymerase, 149–153
- Pfu* DNA polymerase, use of degenerate primers with for PCR, 346–347
- Phosphoramidite chemistry, synthesis of oligonucleotide with, 223–227
- Phosphothioate linkages, 3'-terminal, amplimers with retard degradation and diminish mispriming, 131–136
- Point mutations, multiple, detection of with fluorescence-based SSCP, 323–326
- Polymerase chain reaction. *See* PCR
- Polymorphisms
 length, rapid determination of allele frequencies at loci with, 313–317
- RAPD, reproducibility of among laboratories, 341–345
- Primers
 degenerate, use of with *Pfu* DNA polymerase for PCR, 346–347
 lock-docking oligo(dT), for 5' and 3' RACE-PCR, 144–148
 mismatched, use in MAMA, 14–20
 pairs, optimization with TNK buffers, 234–240
 selection, effect on artifactual deletion of tandem repeat during PCR, 263–265
 sequence influences optimum concentration of DMSO, 89–90
- Proofreading. *See* Fidelity; *see also* specific enzymes
- Prostate cancer, PCR-based analysis of DNA from autopsied tissue from, 354–355
- Protease digestion, effect on in situ hybridization detection of PCR-amplified DNA, 305–312
- Proteins, method for generating terminal and internal deletions starting from cDNA for corresponding mRNA, 172–174
- Quantitation
 endomycorrhizal fungi colonizing roots, 76–80
 HCV RNA in plasma, 241–249
 issues of in PCR, 1–9
 mRNA, rapid synthesis of DNA deletion constructs for, 66–69
 nucleic acids, 1–9
 and RT-PCR in virology, 191–196
- RACE PCR, lock-docking oligo(dT) primer for 5' and 3', 144–148
- Random amplified polymorphic DNA analysis, reproducibility of, 341–345
- Randomization, genes, use of PCR mutagenesis for, 28–33
- RAPD. *See* Random amplified polymorphic DNA analysis
- Rapid amplification of cDNA ends. *See* RACE
- ras* allele, transforming, measurement of copies of among wild-type allele using MAMA, 14–20
- ras* gene mutations, detection of with fluorescence-based SSCP, 323–326
- ras* sequence, use of booster PCR to improve specificity and yield for SSCP, 45–50
- Reproducibility, of RAPD among laboratories, 341–345
- Restriction enzyme analysis, with partial digestions of PCR products, 228–233
- Restriction fragments, from large DNA molecules, ligation-mediated PCR of, 21–27
- Restriction site oligonucleotide, use of in method for retrieving unknown sequence, 318–322
- Restriction-site PCR, for unknown sequence retrieval, 318–322
- Reverse transcriptase
 in situ PCR, RNA targets, 117–123
 rapid PCR, analysis of rare gene transcripts quantitatively with, 137–143
- Reverse transcription
 modified, and PCR for selective detection of colinear genes, 258–260
 PCR, use of stock solutions to simplify mRNA quantitation, 351–353
- RNA
 concentration, effect of on cDNA synthesis for DNA amplification, 86–88
 low copy numbers, detection with reverse transcriptase in situ PCR, 117–123
 quantitative analysis, PCR standards for, 1–9
- Roche Specimen Washing Solution, versus Ficoll-Hypaque for PBL separation, 149–153
- rPCR, for random amplification of whole DNA sequences, 185–190
- RS-PCR. *See* Restriction-site PCR
- RSO. *See* Restriction site oligonucleotide
- RT-RPCR. *See* Reverse transcriptase rapid PCR
- Sample preparation, for small-volume PCR, 261–262
- Saturation mutagenesis, with Mod-PCR, 210–217
- Sequence
 diversity, HIV-1, rapid characterization of with DGGE and automated sequencing, 293–300
 unknown
 cloning with dU-containing linkers, 328–332
 retrieval with restriction-site PCR, 318–322
- Sequence tagged sites, use of PCR buffer optimization to screen large numbers, 234–240
- Sequencing, 3' and 5' ends of cDNA transcripts, use of lock-docking oligo(dT) primer, 144–148

Sequencing

- automated, combined with DGGE for rapid characterization of HIV-1 sequence diversity, 293-300
- genomic, possible use of ligation-mediated PCR, 21-27
- PCR, of murine Ig genes using *E. coli* ssDNA-binding protein, 99-101
- shotgun, use of adapter tags for fragment rescue, 21-27
- Sex-determining region of Y chromosome. *See* SRY-box motif
- Short tandem repeat locus, determination of allele frequencies at in von Willebrand factor gene, 313-317
- Simian immunodeficiency virus, PCR-derived library of random point mutations in V3 region, 301-304
- Single-cell analysis, detection of BLV proviral DNA, 333-340
- Single-strand conformation polymorphism analysis
 - detection of p53 mutations in human tumors, 96-98
 - fluorescence-based, for detection of multiple point mutations, 323-326
 - method for producing p53 exons suitable for, 250-252
 - specificity and yield for increased with booster PCR, 45-50
- Single-stranded DNA-binding protein, effect on in situ hybridization detection of PCR-amplified DNA, 305-312
- SIV. *See* Simian immunodeficiency virus
- Small-volume PCR, sample preparation for, 261-262
- SOE method. *See* Spliced overlap extension method
- Specificity
 - increased for SSCP with booster PCR, 45-50
 - increased with hybrid-selected PCR, 41-44
- Spliced overlap extension method, use with PCR to generate random point mutations in V3 region of SIV, 301-304
- SRY-box motif, demonstration of evolutionary conservation with PCR, 218-222
- SS. *See* Sucrose synthase
- SSB. *See* Single-stranded DNA-binding protein
- Stock solutions, use of to simplify mRNA quantitation by RT-PCR, 351-353
- Stoffel fragment, expression, purification, and enzymatic characterization, 275-287
- STR. *See* Short tandem repeat

STS. *See* Sequence tagged sites

- Subtracted cDNA library, construction with asymmetric PCR, 204-209
- Sucrose synthase, amplification and cloning of with anchored PCR, 70-75
- 3' to 5' exonuclease activity, restriction to proofreading by use of 3'-sulfurized amplification amplimers, 131-136
- 3'-Sulfurization, and reduction of 3' to 5' exonuclease truncation of amplimers, 131-136
- Tailing procedure, and overhangs, improved method for cloning PCR fragments, 81-82
- Tandem repeat, artifactual deletion during PCR, effect of primer selection on, 263-265
- Taq* DNA polymerase
 - method for reversing inhibitory effect of heparin on, 356-358
 - mispriming by, reduced by amplimers with 3'-terminal phosphothioate linkages, 131-136
 - utilization of sulfurized amplimers, 131-136
- Taq* Pol I. *See* *Thermus aquaticus* DNA polymerase
- Taq* polymerase terminal transferase-like activity, mutations generated by, 253-257
- Templates
 - hybrid-selected, use of to increase PCR specificity, 41-44
 - mixed allelic, PCR amplification in direct proportion to stoichiometric fraction of each, 112-116
- Thermococcus litoralis* Vent DNA polymerase, mutations induced by during DNA amplification, 288-292
- Thermus aquaticus* DNA polymerase I, expression, purification, and enzymatic characterization, 275-287
- Tissue biopsy, formalin-fixed, reliable typing of DNA amplified from, 175-176
- TNK buffers, use in screening large numbers of STSs, 234-240
- Transcription, RNA polymerase-mediated of PCR products, and in vitro translation of truncated proteins, 172-174
- Transcripts, rare, quantitative analysis of with RT-RPCR, 137-143
- TRF. *See* Fluorometry, time-resolved
- Tth* DNA polymerase, use of transposon-based model system for long-distance PCR, 51-59

UDG. *See* Uracil DNA glycosylase; Uracil N-glycosylase

- Universal primers, for restriction-site PCR, 318-322
- Unknown fragments, amplification of with ligation-mediated PCR, 21-27
- Uracil DNA glycosylase, and PCR, method for site-directed mutagenesis, 124-130
- Uracil N-glycosylase, dU excision with to create cohesive ends of PCR fragments, 328-332
- Urine, immunomagnetic recovery of *Chlamydia trachomatis* from and colorimetric DNA detection, 167-171
- UV light, in vivo footprinting with, 107-111
- Vapor barrier, use of paraffin wax for in PCR, 180-181
- Variable 3 region, SIV, PCR-derived library of random point mutations in, 301-304
- Variable number of tandem repeat region, determination of allele frequencies at, 313-317
- Variable number tandem repeat loci, automated DNA profiling by fluorescent tagging, 34-40
- Vent DNA polymerase
 - deficient in proofreading 3' to 5' activity, fidelity of, 288-292
 - degradation by is retarded by amplimers with 3'-terminal phosphothioate linkages, 131-136
 - Thermococcus litoralis*, mutations induced by during DNA amplification, 288-292
 - utilization of sulfurized amplimers, 131-136
- Virology, quantitative PCR and RT-PCR in, 191-196
- Viruses, RNA, detection with reverse transcriptase in situ PCR, 117-123
- VNTR. *See* Variable number tandem repeat
- von Willebrand factor gene, determination of allele frequencies at short tandem repeat locus in, 313-317
- Yersinias, pathogenic, PCR assay, 91-92
- Yield, increased for SSCP with booster PCR, 45-50

VOLUME 2, AUTHOR INDEX

Abramson, R.D., 275
 Adriano, T., 223
 Allen, M., 182
 Andersen, J.K., 172
 Andersson, B., 293
 Bagnarelli, P., 191
 Bambot, S.B., 266
 Benson, J.M., 45
 Benson, P.D., 354
 Bickham, J.W., 228
 Blanchard, M.M., 234
 Bloch, W., 305
 Bolander, M.E., 318
 Borson, N.D., 144
 Bradley, W.G., 172
 Breakefield, X.O., 172
 Buell, R.D., 272
 Bush, A., 341
 Cadwell, C.R., 28
 Casareale, D., 149
 Cassiman, J.J., 348
 Cattaneo, R., 356
 Cha, R.S., 14
 Chang, S.-Y., 275
 Chen, D., 351
 Chiang, L.W., 210
 Conant, R., 163
 Coriat, A-M., 218
 Crespiatico, L., 356
 Cutler, A.J., 93
 Da, Yang, 333
 Dahlen, P., 157
 Daniel, L.J., 241
 Day, N.K., 272
 Day, P.J.R., 328
 de Noronha, C.M.C., 131
 Desrosiers, R.C., 301
 Diaco, R., 149
 Dias, C., 288
 Domier, L., 341
 Dotti, G., 163
 Drewes, L.R., 144
 Falcinelli, C., 258
 Fedak, G., 341
 Feinstein, D.L., 66
 Ferre, F., 1
 Flora, S., 99
 Fortina, P., 163
 Froussard, P., 185
 Galea, E., 66
 Gallery, F., 305
 Gelfand, D.H., 275
 Gibbs, R.A., 293
 Gill, P., 34
 Glickman, B.W., 250
 Good, R.A., 272
 Gorevic, P.D., 117
 Gorgone, G.A., 117
 Guisti, W.G., 223

Guo, C., 348
 Gurvita, A., 261
 Gustavsson, I., 175
 Gyllensten, U., 175, 182
 Haas, G.P., 354
 Harry, J.L., 218
 Hayashi, K., 10
 Hedrum, A., 167
 Heidecker, G., 124
 Hitchcock, W., 163
 Hodgall, E., 157
 Hom, R., 305
 Hooper, W.C., 45
 Houge, G., 204
 Howe, M.M., 210
 Hu, C-Y., 182
 Hurskainen, P., 157
 Hurte, I., 175
 Iitiä, A., 157
 Ishaq, M., 263
 Ishino, Y., 323
 Johnson, L.B., 89
 Jones, D.H., 197
 Joyce, G.F., 28
 Kaplan, G., 154
 Kasha, K., 341
 Kato, I., 323
 Keohavong, P., 14, 288
 Kidd, K.K., 112
 Kim, Won, 341
 Kirchhoff, F., 301
 Kishimoto, Y., 10
 Klebe, R.J., 351
 Knittel, T., 346
 Kovari, I., 210
 Kumar, A.S., 70
 Kusser, W.C., 250
 Lai, L.Y.C., 261
 Lalonde, M., 76
 Landre, P.A., 275
 Laroche, A., 341
 Lawyer, F.C., 275
 Leigh, D.A., 261
 Lévesque, C., 76
 Levin, D.B., 250
 Lewin, H.A., 333
 Lewis, D.E., 293
 Ling, L., 288
 Lucas, W.T., 41
 Lundberg, J., 167
 Lutz, C.T., 253
 MacConnell, P., 117, 305
 Macoska, J.A., 354
 Magnuson, V.L., 351
 Makino, R., 10
 Malmgren, C., 175
 Manzin, Al., 191
 Maretzki, A., 70
 Margiotta, M., 117
 Marynen, P., 348
 Masoud, S.A., 89

Massino, C., 191
 McClure, M., 154
 McDonald, B., 261
 Menzo, S., 191
 Mirsky, M.L., 333
 Mitchell, D.B., 81
 Molnar, S.J., 341
 Monokian, G., 163
 Moore, P.H., 70
 Morales, J.C., 228
 Müller, U., 218
 Mullins, J.I., 131
 Neilan, B.A., 261
 Nocco, A., 356
 Nowotny, P., 234
 Nowotny, V., 234
 Nuovo, G.J., 117, 305
 Ogata, N., 272
 Ohler, L.D., 51
 Pacek, P., 305
 Pahlson, C., 167
 Pallen, M.J., 91
 Parrella, T., 163
 Patton, J.C., 228
 Penner, G.A., 341
 Pfeifer, G.P., 107
 Phillips III, J.A., 154
 Phillips, D.J., 45
 Picard, D., 346
 Poli, F., 356
 Pope, S., 34
 Pottahil, R., 149
 Pruckler, J.M., 45
 Puckey, L.H., 91
 Quint, W., 258
 Rapley, R., 99
 Rappaport, E., 163
 Rashtchian, A., 124
 Raskin, S., 154
 Robertson, J.M., 34
 Romeo, J.M., 241
 Rose, E.A., 51
 Rosenbaum, H., 86
 Ruano, G., 112
 Ruggli, N., 81
 Russell, A.J., 266
 Saiki, R., 275
 Sajantila, A., 305
 Sakr, W., 354
 Saldeen, T., 175
 Salo, W.L., 144
 Sarkar, G., 318
 Schwartz, E., 163
 Scoles, G., 340
 Sekiya, T., 10
 Sharpe, P.T., 218
 Shimada, A., 323
 Siitari, H., 157
 Simon, L., 76
 Sirchia, G., 356
 Smith, c., 327

Soto, D., 96
Sparkman, D.R., 180
Steffensen, B., 351
Stoffel, S., 275
Stoner, G.L., 263
Sukumar, S., 96
Sullivan, K.M., 34
Surrey, S., 163
Syvanen, A.-C., 305
Taillon-Miller, P., 234
Takahashi-Fujii, A., 323
Tan, S.S., 137
Thilly, W., 14
Thilly, W.G., 288
Thornton, C.G., 124
Titlow, C.C., 172
Top, B., 83
Tratschin, J.-D., 81
Trofatter, J.A., 172
Turkeri, L.N., 354
Turner, R.T., 318
Uhlén, M., 167
Ulrich, P.P., 241
Uwanogho, D., 218
Valenza, A., 191
van Belkum, A., 258
van Doorn, L.-V., 258
Varaldo, P.E., 191
Vnencak-Jones, C., 154
Vuust, J., 157
Vyas, G.N., 241
Walker, M.R., 328
Walker, R., 99
Wang, H., 93
Weiner, D.B., 86
Weis, J.H., 137
White, F.F., 89
Williams, W.V., 86
Winistorfer, S.C., 197
Wise, R., 341
Wren, B.W., 91
Yazyu, H., 10
Ying, J.-H., 293
Youngner, J.S., 41
Yournon, J., 60
Zarbl, H., 14

Instructions for Authors

Submission of Papers

PCR Methods and Applications welcomes high-quality research papers that describe improvements in PCR methodology, new amplification methods, or the results of PCR application. The journal also publishes review and commentary articles, technical tips, and reader correspondence. All submissions to the journal will be peer-reviewed.

The journal accepts primary research papers and technical tips that present original research which has not previously been published. Submission to the journal implies that a paper is not currently being considered for another journal or book. It is also understood that investigators who submit research papers to the journal are prepared to make available to qualified academic researchers materials needed to duplicate their research results.

Review articles are commissioned. Authors wishing to submit review articles should first contact the Editor.

Contributors should submit their papers to:

Judy Cuddihy, Editor
PCR Methods and Applications
Cold Spring Harbor Laboratory
POB 100, 1 Bungtown Road
Cold Spring Harbor, New York 11724-2203
USA

Phone 516-367-8492
FAX 516-367-8532

One original and two copies of the manuscript should be submitted. Original photographs should be supplied with each copy.

Manuscript preparation

Papers accepted by the journal will occupy between 2 and 10 journal pages. A manuscript of 5 to 25 typed, double-spaced pages total (including methods, references, and figure legends) will translate to this length. Computer printouts should be of letter quality, and each page should be labeled with the first author's name and a page number. All figures should be labeled with the first author's name, the figure number, and an indication of the top. The size of figures will be adjusted to fit the journal format; therefore, please try to keep labels, symbols, and other call-out devices in proportion to the figure size and detail. Figures should be supplied as high-quality

glossy prints. Authors wishing to publish four-color art must pay part of the costs; price estimates will be provided on acceptance of a paper.

The following order of manuscript sections is preferred: Title page, abstract, introduction, methods, results, discussion, acknowledgments, references, tables, figure legends. The methods presented should be detailed enough to allow any qualified researcher to duplicate the results. References are cited by number in the text and the reference list should be numbered in the order the references are cited in the text. Bibliographic information should be supplied in the following order. For journal articles: Authors, year, article title, journal title, volume inclusive page numbers. For books: Authors, year, chapter title, book title, editors' names, volume, inclusive page numbers, publisher, city of publication.

Accepted manuscripts

Accepted manuscripts should be supplied on 3 1/2- or 5 1/4-inch discs to expedite typesetting. Please supply the manuscript as an ASCII file if possible. If a word-processing file is being sent, please do not use any underscoring, italic, or boldface; spell out special characters (Greek, math); use two carriage returns at the end of each paragraph, subheads, and list items. Indicate on the disc: computer brand name, type of file (text or word-processing), name of software, and disc format.

Proofs are considered the final form of the paper and correction can be made only in the case of factual errors. If additional information must be added at this stage, it should be in the form of "Note added in proof," subject to the approval of the editors.

Reprints may be ordered; a form will be included with the proofs.

GENE RESEARCH

Improve your PCR process!

Optimizing each part of the pre- and post-PCR* process — primers, sample preparation, and product detection — maximizes the speed and cost efficiency of the process as a whole. Now laboratories can complete their research faster, more economically and with reliable results, by improving the critical steps of the PCR process using products from Beckman.

MAKE YOUR OWN OLIGONUCLEOTIDES IN LESS TIME, FOR LESS COST

Substantial time and cost advantages can be gained by synthesizing high-quality oligonucleotides immediately on demand. New from Beckman, the Oligo 1000 DNA Synthesizer simplifies oligonucleotide synthesis so that any researcher can easily make high-quality, research-ready oligonucleotides in four to five hours. No further purification is required prior to using your custom oligonucleotides in the PCR process.



Additionally, the Oligo 1000 DNA Synthesizer reduces costs by 30% or more. Scale of synthesis as low as 0.03 μ mol can be used. And reagent life is twice as long as is currently available on other DNA synthesizers.

AUTOMATE THE TEDIOUS SAMPLE PREPARATION STEPS

The BIOMEK® 1000 BioRobotics System from Beckman is ideally suited for precise and efficient pre- and post-PCR sample handling.¹ This fully automated workstation allows you to process thousands of samples per day. Accuracy and reproducibility of low volume pipetting reduces reagent costs and provides consistent reactions. Its ability to interface with a variety of labware offers the flexibility of using standard PCR plates and tube formats. Plus, contamination is effectively controlled with disposable aerosol-barrier pipette tips.

IMPROVE YOUR DETECTION THROUGH HIGHER SENSITIVITY AND LOWER SAMPLE CONSUMPTION

Laser-induced fluorescence (LIF) detection is ideally suited to improve detectability in capillary electrophoresis. The P/ACE™ 2000 Series Capillary Electrophoresis System with LIF detection from Beckman offers an alternative method to classical electrophoretic techniques for verification of the size and purity of PCR products. LIF sensitivity is comparable to autoradiography, delivering up to 400X better sensitivity than CE with UV detection using only nanoliters of the product.² PCR products prestained with intercalating dyes can be analyzed at extremely low levels. Plus, the P/ACE 2000 is fully automated; up to 23 samples may be loaded.



Start with high quality primers, automate sample preparation, and improve the detection process.

REACH THE FINISH LINE FASTER

Beckman products optimize accuracy with automation and operational simplicity before and after the amplification step. This assurance of lower cost, error-free performance is The Beckman Plus that will help you reach the finish line faster.


Ask your Beckman representative for free applications and technical information about DNA synthesis, BioRobotics, capillary electrophoresis, centrifugation, spectrophotometry, and other gene research products by calling 1-800-742-2345 (U.S.) or your local Beckman office.

* PCR is covered by U.S. patents owned by Hoffman-La Roche Inc.

¹ Mark Holodniy, Mark A. Winters and Thomas C. Merigan. *BioTechniques* 1992, Vol. 12, a: 1, 36-39.

² Herbert E. Schwartz and Kathi J. Ulfelder. *Anal. Chem.* 1992, 1737-1740.

BECKMAN



Introducing the first agarose that can challenge polyacrylamide.

MetaPhor agarose

Polyacrylamide

Until now, when you wanted the finest resolution of PCR* products and small DNA fragments (less than 800 bp), you probably made a polyacrylamide gel. Preparing that gel, however, was tedious and time-consuming.

MetaPhor™

But now there's something better. It's a new kind of agarose that not only offers speed and convenience, but also has twice the resolution capabilities of any other agarose. It's new MetaPhor™ agarose from FMC.

In fact, as you can see from the above results, MetaPhor agarose gives you resolution so fine (down to a 4 bp difference) that it rivals polyacrylamide. And we think that makes it a clear winner.

Just dissolve MetaPhor agarose in 1X TBE buffer, cast and chill the gel in your submarine chamber, load your samples, and go. It's as easy as that.

So take the MetaPhor challenge, and see how our new MetaPhor agarose performs. When you do, you'll understand why scientists who want the best go straight to the source. To learn more, or to place your order, call us today at **800-341-1574**.



Go straight to the source.

For Research Use Only. Not for use in diagnostic procedures.
FMC and MetaPhor are trademarks of FMC Corporation. U.S. Patent No. 5,143,646; applications in other countries. ©1993 FMC Corporation.
FMC BioProducts, 191 Thomaston Street, Rockland, ME 04841. Customer Service: 800-341-1574 Technical Service: 800-521-0390 FAX: (207) 594-3491
FMC BioProducts Europe, Risingvej 1, DK-2665 Vallengbaek Strand, Denmark. Tel.: 45-42-73-11-22 FAX: 45-42-73-56-92

*The PCR process is covered by U.S. patents owned by Hoffmann-LaRoche, Inc.